These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 27614938)
1. Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? Konstam MA JACC Heart Fail; 2016 Oct; 4(10):823-825. PubMed ID: 27614938 [No Abstract] [Full Text] [Related]
2. Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. Vaduganathan M; McMurray JJV; Solomon SD Eur J Heart Fail; 2020 Sep; 22(9):1525-1530. PubMed ID: 32741093 [No Abstract] [Full Text] [Related]
3. [Angiotensin-neprilysin inhibition in ckd: does it confer a double benefit?]. Wojtaszek E Wiad Lek; 2019; 72(11 cz 2):2228-2231. PubMed ID: 31860842 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor-Neprilysin Inhibition Therapy and Improved Exercise Parameters in Heart Failure with Reduced Ejection Fraction. Schwartzmann P Arq Bras Cardiol; 2020 Nov; 115(5):828-829. PubMed ID: 33295444 [No Abstract] [Full Text] [Related]
5. Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition". Hubers SA; Brown NJ Circulation; 2016 Jul; 134(3):e11-2. PubMed ID: 27436883 [No Abstract] [Full Text] [Related]
6. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Singh JS; Lang CC Vasc Health Risk Manag; 2015; 11():283-95. PubMed ID: 26082640 [TBL] [Abstract][Full Text] [Related]
8. Renal Safety of de Novo Angiotensin-Neprilysin Inhibition in Older Adults: Insights From a Population-Based Analysis. Yao RJR; Hawkins NM J Card Fail; 2023 Feb; 29(2):147-149. PubMed ID: 36529316 [No Abstract] [Full Text] [Related]
9. Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. de Diego C; González-Torres L; Núñez JM; Centurión Inda R; Martin-Langerwerf DA; Sangio AD; Chochowski P; Casasnovas P; Blazquéz JC; Almendral J Heart Rhythm; 2018 Mar; 15(3):395-402. PubMed ID: 29146274 [TBL] [Abstract][Full Text] [Related]
11. Heart failure: another new PARADIGM in treatment for heart failure? Geach T Nat Rev Cardiol; 2015 Jan; 12(1):4. PubMed ID: 25445135 [No Abstract] [Full Text] [Related]
12. Is there a place for a dual angiotensin receptor-neprilysin inhibitor in the treatment of hypertension? Burnier M J Hypertens; 2017 Apr; 35(4):726-728. PubMed ID: 28248903 [No Abstract] [Full Text] [Related]
13. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Lewis GA; Schelbert EB; Miller CA N Engl J Med; 2020 Mar; 382(12):1182. PubMed ID: 32187480 [No Abstract] [Full Text] [Related]
14. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Yazdani B; Lutz N; Krämer BK N Engl J Med; 2020 Mar; 382(12):1181-1182. PubMed ID: 32187479 [No Abstract] [Full Text] [Related]
15. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Baptista R; Moraes-Sarmento P; Fontes-Carvalho R N Engl J Med; 2020 Mar; 382(12):1181. PubMed ID: 32187478 [No Abstract] [Full Text] [Related]
16. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Gupta K; Bajaj NS N Engl J Med; 2020 Mar; 382(12):1180-1181. PubMed ID: 32187477 [No Abstract] [Full Text] [Related]
17. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. van de Bovenkamp AA; van Rossum AC; Handoko ML N Engl J Med; 2020 Mar; 382(12):1180. PubMed ID: 32187476 [No Abstract] [Full Text] [Related]
18. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure. Prenner SB; Shah SJ; Yancy CW Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636 [TBL] [Abstract][Full Text] [Related]
19. Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era. Warner AL; Lu L; Ghaznavi Z; Jackevicius CA Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008936. PubMed ID: 36252108 [TBL] [Abstract][Full Text] [Related]
20. Letter by Rajapakse et al Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition". Rajapakse NW; Kuruppu S; Ian Smith A Circulation; 2016 Jul; 134(3):e9-e10. PubMed ID: 27436888 [No Abstract] [Full Text] [Related] [Next] [New Search]